Trials / Completed
CompletedNCT04044898
Pharmacokinetics and Safety of ALA in Acne Vulgaris
A Pharmacokinetics and Safety Study of Aminolevulinic Acid Hydrochloride Topical Powder in Subjects With Moderate to Severe Facial Acne Vulgaris.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALA 5% | prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose |
| DRUG | ALA 10% | prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose |
Timeline
- Start date
- 2021-01-12
- Primary completion
- 2021-07-30
- Completion
- 2021-12-06
- First posted
- 2019-08-05
- Last updated
- 2022-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04044898. Inclusion in this directory is not an endorsement.